Thursday, October 29, 2026

Back to today

From X

@StableBread

Fajasy on X

The first thing I said I’d watch on Quantum $QMCO in my August 16 update was $IBM’s tape drive supply, since CEO Hugues Meyrath said on the June-quarter call that “customers’ demand remains stronger than our ability to fulfill it.” The LTO Program, the group of $HPE, $IBM, and $QMCO that sets the LTO tape standard, reported on September 1, 2026 that tape capacity shipped in Q1 2026 rose 57% from Q1 2025. The 57% measures data capacity, and each new LTO generation holds more data per cartridge, so capacity shipped can grow faster than the number of cartridges sold. Meyrath said on the June-quarter call that $QMCO’s $82.0M ±$2M revenue guidance for the September quarter is only “mildly up” because tape drive supply had stayed “flat for the past handful of months.” $IBM, which supplies the drives, had told $QMCO it would increase production toward the back half of the year, but Meyrath said the increase still hadn’t shown up as of August. So by Meyrath’s account, $IBM’s drive supply, not demand, limits how much $QMCO can sell for now. $QMCO’s quarterly revenue has risen from $62.7M in the September 2025 quarter to $80.8M in the June quarter. Secondary storage, which $QMCO’s 10-K describes as “primarily tape storage systems,” drove the growth. It doubled from a year earlier to $37.0M in the June quarter, 46% of total revenue, up from 29%. That $18.5M increase was more than the $16.5M rise in total revenue, since primary storage, $QMCO’s file and object storage systems, fell to $8.5M from $12.5M.
BMBL 2026-10-21

Bumble is being taken private

Bumble agreed to a $6.05-per-share cash sale to Ithaca Holdings, 136% above its October 2 share price.

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

ContextLogic

ContextLogic’s US Salt holds about 23% of the US and Canadian pharmaceutical-grade salt market, one of only two suppliers, supporting…

Jumia

Jumia’s January 2028 $7/$15 call spread risks $1.15 for up to $6.85 if cost cuts and marketplace growth deliver adjusted EBITDA and…

Performance Review: H1 2026

REIT holdings outperformed in H1 2026, with Veris Residential sold in a $19-per-share take-private and FrontView REIT trimmed after a 78%…

Stock Trade Compilation Diez

E.W. Scripps, Team Internet, Monro, doValue and Inter & Co feature as special-situation trades involving mergers, asset sales, leverage and…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.